archive-com.com » COM » I » ISIS-INNOVATION.COM

Total: 451

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Material & Reagent Sales - Page 4 of 4 - Isis Innovation
    Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports About Groups People Overview Board Overview Networks Oxford Innovation Society Isis Angels Network Other Networks Isis Innovation in China Jobs Other Languages Contact us Technologies Available Explore Technologies for License Intellectual Property IP for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Share this Material Reagent Sales Reagents created by Oxford University researchers can be purchased by third parties from Reagents Isis this includes hybridomas cell lines mouse models and small molecule research tools The availability of research reagents from Isis Innovation is constantly changing so email reagents Isis with your specific requirements Filter by category OR Search all Reset Other Reagents Materials Murine Models Hybridomas Cell Biology Tools Antigen Rat Antigen Mouse Antigen Human Antigen fungi plant application

    Original URL path: http://isis-innovation.com/technologies-available/materials-reagent-sales/page/4/ (2016-05-01)
    Open archived version from archive


  • Isis spin-out NaturalMotion bought for $527m - Isis Innovation
    Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home All News Isis spin out NaturalMotion bought for 527m Share this Isis spin out NaturalMotion bought for 527m 13th February 2014 Acquisition by US games company Zynga one of the largest for a European spin out Isis Innovation worked with Zoology researcher Torsten Reil to protect his intellectual property develop a business plan and introduce first round investors The company was spun out in 2001 US social games company Zynga has now finalised the acquisition of Natural Motion for more than 527m The University as a NaturalMotion shareholder will benefit from more than 30m in cash and shares from the deal NaturalMotion Ltd started in 2001 based on the work of Oxford Zoology DPhil student Torsten Reil the company s CEO since foundation Torsten was a neural researcher developing computer simulations of nervous systems based on genetic algorithms His programmes used natural selection to evolve their own means of locomotion allowing more realistic animations of human and animal movement Torsten quickly saw the commercial potential of the technology called Dynamic Motion Synthesis DMS With the help of the University s technology transfer company Isis Innovation Ltd he co founded NaturalMotion for the development use and sale of DMS The Oxford University Challenge Seed Fund provided some initial funding for the new business while Isis Innovation helped Torsten apply for a patent Isis also introduced the new company to further investment from business angels many of them Oxford based Following NaturalMotion s launch the University continued to invest in the company s development through Oxford Spin out Equity Management OSEM The University established OSEM in 2008 to manage its equity in spin outs and make further cash investments when appropriate OSEM s backing was complemented by investment from top tier venture capital firms Balderton Capital and Benchmark The continued support helped NaturalMotion expand to its current size of around 260 employees with offices in Oxford London Brighton and San Francisco Professor Andrew Hamilton Vice Chancellor of the University of Oxford said Torsten Reil has built up a remarkable business based on his research at Oxford into computer simulations of nervous systems NaturalMotion is now an outstanding example of how our academic excellence translates into high quality jobs and commercial success The scale of the acquisition and the benefit to the University is a terrific endorsement of our strategy of commercialising University Intellectual Property and continued investment in our spin outs The acquisition by NASDAQ listed Zynga represents the first major sale of a University spin out since OSEM s formation in 2008 Dr Chris Towler Director of OSEM said I am thrilled that as a major investor and shareholder in NaturalMotion OSEM has delivered a substantial capital gain for the University OSEM has enjoyed a close working relationship with Torsten and the other major shareholders over many years This is

    Original URL path: http://isis-innovation.com/news/isis-spin-naturalmotion-bought-527m/ (2016-05-01)
    Open archived version from archive

  • Oxford Antibiotics - Isis Innovation
    Board Overview Networks Oxford Innovation Society Isis Angels Network Other Networks Isis Innovation in China Jobs Other Languages Contact us Technologies Available Explore Technologies for License Intellectual Property IP for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities Oxford Antibiotics Share this Oxford Antibiotics An innovative bio pharmaceutical company developing novel first in class antibiotics Opportunity Team Dr Alexander Pretsch CEO Prof Mark Moloney Academic Founder Vision To bring a new first in class drug into the antibiotic market that provides a clear commercial advantage by following the market needs for new modes of action and good AMR better toxicity stability profiles and the need for low production costs Target Markets The global antibacterial market has been growing at a CAGR of 9 5 In 2014 the market

    Original URL path: http://isis-innovation.com/opportunities/oxford-antibiotics/ (2016-05-01)
    Open archived version from archive

  • Oxbridge White - Isis Innovation
    Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities Oxbridge White Share this Oxbridge White Perovskite LEDs Opportunity Oxbridge White Limited is a joint venture between two world leading universities Oxford and Cambridge and is headed by Professor Henry Snaith and Professor Sir Richard Friend Approximately 25 of the global electricity demand is used for lighting which accounts for 1 9 Gt of CO2 emissions In order to reduce the energy demand for lighting white light emitting diodes LEDs are becoming increasing prevalent which are much more efficient than incandescent bulbs and fluorescent tube lighting This drive to higher efficiency lighting is rapidly increasing the use of LEDs in the entire lighting market leading to a current 20 billion global market1 A standard white light LED is typically composed of a blue GaN LED with a coating of phosphor s The role of the phosphor is to absorb a certain fraction of the blue light down convert and reemit this light across the visible spectrum Although effective this suffers from a limited emission in the red spectral region in comparison to the green region resulting in cool white light correlated colour temperature 4000 8000 K and

    Original URL path: http://isis-innovation.com/opportunities/oxbridge-white/ (2016-05-01)
    Open archived version from archive

  • Covatic - Isis Innovation
    Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports About Groups People Overview Board Overview Networks Oxford Innovation Society Isis Angels Network Other Networks Isis Innovation in China Jobs Other Languages Contact us Technologies Available Explore Technologies for License Intellectual Property IP for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities Covatic Share this Covatic Broadcast policy management using semantic technologies Opportunity Covatic is a University of Oxford spin out to be incorporated as a British limited company with headquarters in East London Covatic s aim is to drive the future of the broadcast industry by the practical application of fundamental research using technology in new ways and in new

    Original URL path: http://isis-innovation.com/opportunities/covatic/ (2016-05-01)
    Open archived version from archive

  • Minomic - Isis Innovation
    Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports About Groups People Overview Board Overview Networks Oxford Innovation Society Isis Angels Network Other Networks Isis Innovation in China Jobs Other Languages Contact us Technologies Available Explore Technologies for License Intellectual Property IP for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities Minomic Share this Minomic Next generation prostate cancer testing and screening products Opportunity Summary Minomic is a leading immuno oncology company developing next gen prostate cancer testing and screening products for global markets MiCheck is a new non invasive diagnostic test for prostate cancer using just a blood sample MiCheck is twice as

    Original URL path: http://isis-innovation.com/opportunities/minomic/ (2016-05-01)
    Open archived version from archive

  • EstryX Pharma - Isis Innovation
    for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities EstryX Pharma Share this EstryX Pharma Drug development for next generation multi targeting therapeutics Background EstryX Pharma Limited is a new drug development and discovery company the which will be jointly formed by the University of Bath and the University of Oxford Estryx will bring commercial value to the pioneering work of Prof Barry Potter FMedSci Medicinal Chemistry University of Oxford formerly University of Bath As Chief Scientific Advisor CSA Professor Potter brings to the Company more than two decades of experience at the cutting edge of R D in the design and development of enzyme inhibitors and targeted cancer therapeutics Together with Dr John Normanton the Company s CEO and co founder they were previously responsible for the

    Original URL path: http://isis-innovation.com/opportunities/estryx-pharma/ (2016-05-01)
    Open archived version from archive

  • OxSOL - Isis Innovation
    a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports About Groups People Overview Board Overview Networks Oxford Innovation Society Isis Angels Network Other Networks Isis Innovation in China Jobs Other Languages Contact us Technologies Available Explore Technologies for License Intellectual Property IP for SMEs Material Reagent Sales Easy to use Materials Evaluation Agreement Investment Opportunities Technology investment opportunities Information for Investors Isis Innovation spinouts Oxford Invention Fund University of Oxford Isis Funds Oxford University Consulting Services Academic consulting advice Academic Expertise Showcases Technical Services Technical Services Showcases OUC Clients For University members Contact OUC Innovation Consultancy Technology Transfer Commercialisation Training Technology Transfer Services Technology Commercialisation Innovation Management Case Study Overview Contact us Health Outcomes iOutcomes People Overview Clinical Outcomes Assessments Health Outcome Services FAQs Apply to Use Inspired Works Contact us Incubator News Incubator Services Stages of Development Our Ventures Meet the CEOs Find your CEO match Incubator Team Contact For University Members Consulting Services Support FAQs Register as a consultant Commercialising Your Technology IP patents and licences Starting a company FAQs Isis Startup Incubator Oxford University Hospital NHS Foundation Trust Translational Funding University Hot Desks For Medical Sciences Researchers Contact Us News Events Publications News Events Request further information Technology Showcase 2016 Success Stories Publications Annual Reports Innovation Insights Isis newsletters Comment opinion Other publications reports Home Investment Opportunities Technology investment opportunities OxSOL Share this OxSOL Next generation polymer oxide hybrids Opportunity OxSOL Limited is a spin out based on innovations from the world leading University of Oxford and associated entrepreneurs The Company s patented technology platform of polymer oxide

    Original URL path: http://isis-innovation.com/opportunities/oxsol/ (2016-05-01)
    Open archived version from archive



  •